FGP
ARQT icon

Freestone Grove Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Freestone Grove Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291K Buy
11,084
+6,541
+144% +$152K ﹤0.01% 765
2026
Q1 		$107K Buy
+4,543
New +$116K ﹤0.01% 801
2025
Q1 		– Sell
-35,818
Closed -$499K – 586
2024
Q4 		$499K Buy
+35,818
New +$392K 0.01% 379

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Freestone Grove Partners's ARQT Position: Q2 2026 in Review

Freestone Grove Partners increased its Arcutis Biotherapeutics (ARQT) stake by 144% in Q2 2026, buying an estimated $152K and bringing the position to 11,084 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #765.

Freestone Grove Partners first reported a position in ARQT in Q4 2024 and has held it in 3 quarters since. The position peaked at $499K in Q4 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Freestone Grove Partners held 11,084 shares of Arcutis Biotherapeutics worth $291K as of Q2 2026.
  • Freestone Grove Partners bought 6,541 Arcutis Biotherapeutics shares in Q2 2026, an estimated $152K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #765 holding.
  • Freestone Grove Partners first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 3 quarters since.
  • Freestone Grove Partners's Arcutis Biotherapeutics position peaked at $499K in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.